Lonza Group AG Logo

Lonza Group AG

A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.

LONN | SW

Overview

Corporate Details

ISIN(s):
CH0013841017 (+2 more)
LEI:
549300EFW4H2TCZ71055
Country:
Switzerland
Address:
MÜNCHENSTEINERSTR. 38, 4052 BASEL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lonza Group AG is a Swiss multinational company and a leading global Contract Development and Manufacturing Organization (CDMO) serving the pharmaceutical, biotechnology, and nutrition industries. The company provides integrated services that span from early-stage development to the commercial manufacturing of drug substances and drug products. Lonza specializes in a wide range of advanced technologies, including mammalian and microbial biologics, small molecules, highly potent active pharmaceutical ingredients (APIs), bioconjugates, mRNA, and cell and gene therapies. Founded in 1897, Lonza leverages its extensive scientific and manufacturing expertise to enable its customers to bring innovative and life-enhancing therapies to market for patients worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-23 06:30
Earnings Release
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDM…
English 18.3 KB
2025-10-23 02:00
Earnings Release
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDM…
English 15.5 KB
2025-10-03 09:00
Board/Management Information
Lonza Nominates Claudia Sussmuth-Dyckerhoff as Board Member
English 17.8 KB
2025-10-03 02:00
Board/Management Information
Lonza Nominates Claudia Süssmuth-Dyckerhoff as Board Member
English 14.2 KB
2025-09-12 09:00
Board/Management Information
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez …
English 22.8 KB
2025-09-12 02:00
Board/Management Information
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez …
English 18.8 KB
2025-07-23 06:30
Earnings Release
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sale…
English 42.2 KB
2025-07-23 02:00
Earnings Release
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sale…
English 37.0 KB
2025-07-23 02:00
Earnings Release
Lonza erzielt starkes Ergebnis im ersten Halbjahr 2025 und erhöht Umsatz- und M…
German 36.9 KB
2025-05-27 07:00
Earnings Release
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
English 12.7 KB
2025-05-27 02:00
Regulatory Filings
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
English 9.7 KB
2025-05-15 09:00
Board/Management Information
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
English 14.6 KB
2025-05-15 02:00
Board/Management Information
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
English 11.0 KB
2025-05-10 16:30
AGM Information
Lonza Announces Results of the 2025 Annual General Meeting All Motions Propose…
English 16.3 KB
2025-05-09 06:30
Earnings Release
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in L…
English 15.2 KB

Automate Your Workflow. Get a real-time feed of all Lonza Group AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lonza Group AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lonza Group AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-14 N/A Executive member Buy None 147,442.00 CHF
2025-03-13 N/A Executive member Buy None 107,906.00 CHF
2025-03-12 N/A Executive member Buy None 146,239.00 CHF
2025-03-11 N/A Executive member Buy None 382,476.00 CHF
2025-03-10 N/A Executive member Buy None 771,722.40 CHF
2025-03-07 N/A Executive member Buy None 338,476.00 CHF
2025-03-06 N/A Executive member Buy None 313,416.00 CHF
2025-02-18 N/A Executive member Buy None 164,554.00 CHF
2025-02-14 N/A Executive member Buy None 130,606.00 CHF
2025-02-13 N/A Executive member Buy None 29,500.00 CHF

Peer Companies

Kyivmedpreparat Logo
A leading pharmaceutical producer of antibacterial, generic, and original medicines in various forms.
Ukraine
KMED
KYONGBO PHARMACEUTICAL CO., LTD. Logo
Manufactures APIs and finished drugs, offering global CDMO services from development to production.
South Korea
214390
KYORIN Pharmaceutical Co., Ltd. Logo
Researches, develops, and sells a portfolio of ethical, generic, and OTC medicines.
Japan
4569
Kyowa Kirin Co.,Ltd. Logo
Develops antibody medicines for oncology, nephrology, immunology, and allergy.
Japan
4151
KyungdongPharm Logo
Develops and manufactures Rx/OTC drugs & APIs for cardiology and other chronic conditions.
South Korea
011040
KYUNG NAM PHARM.CO.,LTD. Logo
South Korean maker of OTC medicines, health foods, and cosmetics, known for its Lemona Vitamin C.
South Korea
053950
Kyverna Therapeutics, Inc. Logo
Developing CAR T-cell therapies for durable remission in autoimmune diseases.
United States of America
KYTX
Labiana S.A. Logo
Pharmaceutical CDMO for animal & human health with its own line of vaccines and generics.
Spain
LAB
Labocanna Spolka Akcyjna Logo
Cultivates and distributes medical marijuana and cannabinoid products for clinical and consumer use.
Poland
LCN
Labomar Logo
A CDMO developing custom supplements, medical devices & cosmetics for third-party clients.
Italy
LBM

Talk to a Data Expert

Have a question? We'll get back to you promptly.